The BET inhibitors JQ1 and I‐BET, which compete with acetylation sites for histone binding to the BDs of the BET protein, were developed and exhibited anti‐proliferative effects in various types of cancer.[7, 8] The discovery of BET inhibitors has made BRD4 a potential target for the treatment of a variety of diseases, including cancer and inflammation. The gene discussed is DNER; the disease is cancer.